Ligand Pharmaceuticals | LGND - Umlaufvermögen

Aktienkurs
213.21
Täglich Wechseln
-5.77 -2.63%
Monatlich
-4.49%
Jährlich
103.95%
Q2 Prognose
208.92




Umlaufvermögen Veränderung Datum
Agenus USD 95.28M 38.15M 2026-03
Amgen USD 31.48B 2.42B 2026-03
Anika Therapeutics USD 93.56M 9.8M 2026-03
Arrowhead Research USD 1.84B 665.36M 2026-03
Baxter International USD 6.85B 25M 2026-03
Bristol-Myers Squibb USD 27.21B 2.18B 2026-03
Eli Lilly USD 54.84B 794M 2026-03
Enanta Pharmaceuticals USD 198.68M 5.65M 2025-12
Enviri Corporation USD 722.11M 1.43M 2026-03
Gilead Sciences USD 18.64B 1.25B 2026-03
GlaxoSmithKline GBP 17.76B 251M 2026-03
Glaxosmithkline GBP 23.59B 390.44M 2025-12
Heron Therapeutics USD 228.98M 9.08M 2026-03
Insmed USD 1.61B 181.04M 2026-03
Intrexon USD 23.72M 45.04M 2024-06
Ionis Pharmaceuticals USD 2.94B 52M 2026-03
Karyopharm Therapeutics USD 103.15M 13.4M 2025-12
Ligand Pharmaceuticals USD 865.42M 33.14M 2026-03
MacroGenics USD 182.52M 37.42M 2026-03
Merck USD 35.02B 8.5B 2026-03
Pacira USD 514.96M 33.01M 2026-03
Pfizer USD 42.82B 76M 2026-03
Rigel Pharmaceuticals USD 214.93M 39.53M 2025-09
Sangamo BioSciences USD 49.89M 12.3M 2025-06
Veracyte USD 522.17M 33.8M 2026-03